NCT06450418

Brief Summary

Many people living with neurodegenerative conditions like dementia, motor neuron disease (MND), multiple sclerosis (MS), and Parkinson's disease (PD), suffer from speech problems. Using common digital technologies such as smartphone apps, the investigators can record and analyse speech in detail to provide new information for people living with these conditions, researchers, and healthcare professionals. This study will investigate the use of these digital speech recordings to help diagnose and monitor these conditions. To take part, participants will have either a diagnosis of dementia, motor neuron disease, Parkinson's disease or Multiple Sclerosis, OR they will have no diagnosis of a neurological condition. Researchers will compare people with a diagnosis of a Neurological condition to those without.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
1mo left

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Jul 2024Jun 2026

First Submitted

Initial submission to the registry

February 9, 2024

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 10, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

July 12, 2024

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Last Updated

September 18, 2025

Status Verified

September 1, 2025

Enrollment Period

1.9 years

First QC Date

February 9, 2024

Last Update Submit

September 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Primary outcome measures

    Area under the curve (AUC) of the receiver operating characteristic (ROC) curve for each of the 4 binary classifiers distinguishing between a disease-positive group and a healthy control group.

    24 months

Secondary Outcomes (2)

  • Secondary outcome measure

    24 months

  • Secondary outcome measure

    24 months

Study Arms (5)

Carers/Realtives/ Healthy - No Diagnosis of a Neurodegenerative Disorder

Motor Neuron Disease

Multiple Sclerosis

Dementia

Parkinson's Disease

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants with Neurodegenerative Disorders and their relatives or carers without a diagnosis of a Neurodegenerative disorder.

You may qualify if:

  • A person with a diagnosis of Motor Neuron Disease, Dementia, Multiple Sclerosis, or Parkinson's Disease.
  • A relative or carer of the above who does not report to have a neurological condition.
  • A healthy volunteer who does not report to have a neurological condition.

You may not qualify if:

  • Age \<16 years
  • Significant and uncorrected visual or hearing impairment (precluding use of the App).
  • Lack capacity to consent to project due to cognitive impairment (precluding understanding of the study and use of the App).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NHS Lothian

Edinburgh, United Kingdom

RECRUITING

Related Publications (1)

  • Tam J, Weaver C, Ihenacho A, Newton J, Virgo B, Barrett S, Neale J, Perry D, Smith A, Chandran S, Watts O, Pal S; DASH Consortium. Digital App for Speech and Health Monitoring Study (DASH): protocol for a prospective longitudinal case-control observational study for developing speech datasets in neurodegenerative disorders and dementia. BMJ Open. 2025 Dec 5;15(12):e100222. doi: 10.1136/bmjopen-2025-100222.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Participants can additionally and optionally consent for blood samples to be obtained during the study. These samples will be collected and stored with the intention of exploring emerging blood-based biomarkers.

MeSH Terms

Conditions

DementiaMotor Neuron DiseaseMultiple SclerosisParkinson Disease

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersNeurodegenerative DiseasesNeuromuscular DiseasesDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesParkinsonian DisordersBasal Ganglia DiseasesMovement DisordersSynucleinopathies

Study Officials

  • Suvankar Pal, Prof

    University of Edinburgh

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christine R Weaver, MSc

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2024

First Posted

June 10, 2024

Study Start

July 12, 2024

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

September 18, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations